基因組編輯市場 - 預測 2025-2030

基因組編輯市場預計將從 2025 年的 40.87 億美元成長到 2030 年的 80.18 億美元，複合年成長率為 14.43%。

基因組編輯是一種改變生物體DNA的技術，在農業、醫療保健和科研領域至關重要。其應用包括提高作物產量、診斷和治療疾病以及促進科學發現。受癌症和遺傳疾病發病率上升、投資增加以及政府扶持政策的推動，全球基因組編輯市場正經歷顯著成長。本摘要專為行業專業人士量身定做，重點關注關鍵市場促進因素以及基於2024年及未來市場發展預測的區域趨勢。

市場促進因素

• 癌症和遺傳疾病發生率不斷上升

全球癌症和遺傳疾病的增加持續推動對基因組編輯解決方案的需求。國際癌症研究機構 (IARC) 預測癌症患者數量將大幅增加，其中歐洲預計將從 2020 年的 439.8 萬人成長到 2040 年的 532.3 萬人（成長 21%），北美同期將從 255.7 萬人成長到 352.5 萬人（成長 38%）。預計到 2040 年，亞洲的癌症患者數量將激增 59% 以上。這些令人擔憂的趨勢凸顯了對創新療法的迫切需求，將基因組編輯定位為開發標靶治療的關鍵工具。新型遺傳疾病的發現進一步擴大了這種需求，隨著研究人員利用基因組編輯來治療複雜的病理，推動了市場擴張。

• 增加投資和研究

基因組編輯技術在解決農業和醫療保健領域挑戰的潛力推動了其投資的激增。世界各國政府正積極支持這些進步。例如，英國政府將繼續簡化法規，以促進2024年後農業基因組編輯技術的研發，旨在提高作物產量並確保基因組編輯產品的安全上市。同樣，中國政府也優先發展基於CRISPR技術的創新，以加強糧食安全，並投入了大量的前期資金。這些努力，加上全球研究計畫的配合，預計將透過促進創新和擴大基因組編輯技術的應用，進一步加速市場成長。

地理視角

北美市場領導地位

由於在研發方面大力投入，北美在全球基因組編輯市場佔據主導地位。該地區強大的基礎設施，加上其對日益成長的癌症和遺傳疾病病例的重視，鞏固了其主導地位。學術機構、生技公司和政府機構之間的合作不斷推動基因組編輯應用，確保了北美在市場上的主導地位。

亞太地區快速成長

受醫療支出成長以及遺傳疾病和癌症盛行率上升的推動，亞太地區預計將迎來顯著的市場成長。中國在政府扶持計畫的支持下，廣泛應用CRISPR技術，是推動這項成長的關鍵因素。該地區致力於透過基因組編輯改善醫療保健成果和農業生產力，使其成為全球市場的重要成長中心。

基因組編輯市場正呈現強勁成長勢頭，這得益於癌症和遺傳疾病先進療法需求的不斷成長、全球投資的不斷增加以及政府政策的支持。北美憑藉著良好的投資環境引領產業發展，而亞太地區正逐漸成為高成長地區，尤其是在中國CRISPR技術取得進展的帶動下。這些趨勢凸顯了基因組編輯的變革潛力，使其成為2040年產業創新和投資的焦點。

本報告的主要優點

• 深刻分析：獲得涵蓋主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、垂直行業和其他細分市場。
• 競爭格局：了解全球主要企業所採用的策略策略，並了解正確策略帶來的潛在市場滲透。
• 市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響市場的未來發展。
• 可行的建議：利用洞察力進行策略決策，在動態環境中開闢新的業務流和收益。
• 適用範圍廣：對於新興企業、科學研究機構、顧問公司、中小企業、大型企業都有利且划算。

它有什麼用途？

產業和市場考量、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本支出決策、法律規範與影響、新產品開發、競爭影響

研究範圍

• 2022 年至 2024 年的歷史數據和 2025 年至 2030 年的預測數據
• 成長機會、挑戰、供應鏈前景、法律規範與趨勢分析
• 競爭定位、策略和市場佔有率分析
• 各細分市場和地區（包括國家）的收益成長和預測分析

公司簡介

目錄

第1章執行摘要

第2章市場概述

• 市場概覽
• 市場定義
• 研究範圍
• 市場區隔

第3章 商業景氣

• 市場促進因素
• 市場限制
• 市場機會
• 波特五力分析
• 產業價值鏈分析
• 政策法規
• 策略建議

第4章 技術展望

第5章 基因組編輯市場（依技術類型）

• 介紹
• CRISPR
• 塔倫
• ZFN
• 其他

第6章 基因組編輯市場（依應用）

• 介紹
• 細胞株工程
• 動物基因工程
• 植物性因工程

第7章 基因組編輯市場（依最終用戶）

• 介紹
• 學術研究所
• 生物技術和製藥公司
• 合約研究組織

第8章 基因組編輯市場（按地區）

• 介紹
• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他
• 歐洲
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 其他
• 中東和非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 印尼
  • 其他

第9章競爭格局及分析

• 主要企業和策略分析
• 市場佔有率分析
• 合併、收購、協議和合作
• 競爭儀錶板

第10章 公司簡介

• Thermo Fisher Scientific Inc.
• Merck & Co., Inc.
• Horizon Discovery Group plc
• GenScript
• Sangamo Therapeutics, Inc.
• Danaher Corporation
• Lonza Group AG
• BEX Co., LTD.
• OriGene Technologies, Inc.
• CRISPR Therapeutics

第11章 附錄

• 貨幣
• 先決條件
• 基準年和預測年時間表
• 相關人員的主要利益
• 調查方法
• 簡稱

The genome editing market is expected to grow from USD 4.087 billion in 2025 to USD 8.018 billion in 2030, at a CAGR of 14.43%.

Genome editing, a transformative technique for altering an organism's DNA, is pivotal in agriculture, healthcare, and research. Its applications include enhancing crop yields, diagnosing and treating diseases, and advancing scientific discovery. The global genome editing market has experienced significant growth driven by increasing incidences of cancer and genetic disorders, rising investments, and supportive government policies. This summary, tailored for industry experts, focuses on key market drivers and geographical trends based on developments from 2024 onward, excluding earlier data as requested.

Market Drivers

• Rising Prevalence of Cancer and Genetic Disorders

The global increase in cancer and genetic disorders continues to propel demand for genome editing solutions. The International Agency for Research on Cancer (IARC) projects a significant rise in cancer cases, with Europe expecting an increase from 4.398 million in 2020 to 5.323 million by 2040 (a 21% rise) and North America anticipating growth from 2.557 million to 3.525 million (a 38% increase) over the same period. In Asia, cancer cases are forecasted to surge by over 59% by 2040. These alarming trends underscore the urgent need for innovative treatments, positioning genome editing as a critical tool for developing targeted therapies. The identification of new genetic disorders further amplifies this demand, as researchers leverage genome editing to address complex conditions, driving market expansion.

• Increased Investments and Research

Investments in genome editing have surged, fueled by its potential to address agricultural and healthcare challenges. Governments worldwide are actively supporting these advancements. For instance, in 2024 and beyond, the UK government has continued to streamline regulations to facilitate research and development in genome editing for agriculture, aiming to enhance crop productivity and ensure safe market entry for genome-edited products. Similarly, China's government has prioritized CRISPR-based innovations to bolster food security, building on significant prior investments. These efforts are complemented by global research initiatives, which are expected to further accelerate market growth by fostering innovation and expanding applications of genome editing technologies.

Geographical Outlook

North America's Market Leadership

North America is poised to maintain a dominant share of the global genome editing market, driven by substantial investments in research and development. The region's robust infrastructure, coupled with a strong focus on addressing rising cancer and genetic disorder cases, supports its leadership position. Collaborative efforts between academic institutions, biotech firms, and government agencies continue to advance genome editing applications, ensuring North America's prominence in the market.

Asia Pacific's Rapid Growth

The Asia Pacific region is expected to experience significant market growth, propelled by increasing healthcare expenditures and the rising prevalence of genetic disorders and cancer. China's extensive use of CRISPR technology, supported by government-backed initiatives, is a key driver of this growth. The region's focus on improving healthcare outcomes and agricultural productivity through genome editing positions it as a critical growth hub in the global market.

The genome editing market is on a robust growth trajectory, driven by the escalating need for advanced treatments for cancer and genetic disorders, increased global investments, and supportive government policies. North America leads due to its investment landscape, while the Asia Pacific region is emerging as a high-growth area, particularly with China's advancements in CRISPR. These trends highlight genome editing's transformative potential, making it a focal point for industry innovation and investment through 2040.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2022 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries

Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Genome Editing Market Segmentation

By Technology Type

• CRISPR
• TALEN
• ZFN
• Others

By Application

• Cell Line Engineering
• Animal Genetic Engineering
• Plant Genetic Engineering

By End-User

• Academic & Research Institutes
• Biotechnology & Pharmaceutical Company
• Contract Research Organization

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• UK
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Taiwan
• Thailand
• Indonesia
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GENOME EDITING MARKET BY TECHNOLOGY TYPE

• 5.1. Introduction
• 5.2. CRISPR
• 5.3. TALEN
• 5.4. ZFN
• 5.5. Others

6. GENOME EDITING MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Cell Line Engineering
• 6.3. Animal Genetic Engineering
• 6.4. Plant Genetic Engineering

7. GENOME EDITING MARKET BY END-USER

• 7.1. Introduction
• 7.2. Academic & Research Institutes
• 7.3. Biotechnology & Pharmaceutical Company
• 7.4. Contract Research Organization

8. GENOME EDITING MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Thermo Fisher Scientific Inc.
• 10.2. Merck & Co., Inc.
• 10.3. Horizon Discovery Group plc
• 10.4. GenScript
• 10.5. Sangamo Therapeutics, Inc.
• 10.6. Danaher Corporation
• 10.7. Lonza Group AG
• 10.8. BEX Co., LTD.
• 10.9. OriGene Technologies, Inc.
• 10.10. CRISPR Therapeutics

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key benefits for the stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations